NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Schizophrenia

In brief

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

Key facts

Study ID
NCT06963034
Run by
Neurocrine Biosciences
People needed
284
Starts
2025-05-08
Expected to finish
2027-10-01
Last updated by the study team
2026-03-06

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.